Skip to content
Carbinoxamine
Karbinal (carbinoxamine) is a small molecule pharmaceutical. Carbinoxamine was first approved as Clistin on 1982-01-01. It is used to treat allergic conjunctivitis, allergic rhinitis perennial, angioedema, and vasomotor rhinitis in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
respiratory tract diseasesD012140
otorhinolaryngologic diseasesD010038
eye diseasesD005128
cardiovascular diseasesD002318
skin and connective tissue diseasesD017437
immune system diseasesD007154
Trade Name
FDA
EMA
Karbinal (generic drugs available since 2003-03-19, discontinued: Clistin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Carbinoxamine maleate
Tradename
Company
Number
Date
Products
KARBINAL ERAytu BiopharmaN-022556 RX2013-03-28
1 products, RLD, RS
Show 2 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
carbinoxzamine maleateANDA2023-05-31
karbinal New Drug Application2020-01-16
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
allergic conjunctivitisEFO_0007141D003233H10.44
allergic rhinitis perennialEFO_1001417D012221J30.89
angioedemaEFO_0005532D000799T78.3
vasomotor rhinitisEFO_0007533D012223J30.0
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Carbinoxamine Maleate, Karbinal Er, Aytu
80626672029-03-29DP
95221912027-06-15DP
ATC Codes
R: Respiratory system drugs
— R06: Antihistamines for systemic use
— R06A: Antihistamines for systemic use
— R06AA: Aminoalkyl ethers, systemic antihistamines
— R06AA08: Carbinoxamine
HCPCS
No data
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCARBINOXAMINE
INNcarbinoxamine
Description
Carbinoxamine is an organochlorine compound that is 2-(4-chlorobenzyl)pyridine in which one of the benzylic hydrogens is substituted by 2-(dimethylamino)ethoxy group. It is an ethanolamine-type antihistamine, used as its maleate salt for treating hay fever, as well as mild cases of Parkinson's disease. It has a role as a H1-receptor antagonist, an anti-allergic agent, a muscarinic antagonist and an antiparkinson drug. It is a member of pyridines, a tertiary amino compound and a member of monochlorobenzenes.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CN(C)CCOC(c1ccc(Cl)cc1)c1ccccn1
Identifiers
PDB—
CAS-ID486-16-8
RxCUI20220
ChEMBL IDCHEMBL864
ChEBI ID3398
PubChem CID2564
DrugBankDB00748
UNII ID982A7M02H5 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 181 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
14 adverse events reported
View more details